Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
88 hedge funds and large institutions have $555M invested in Regulus Therapeutics in 2015 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 38 increasing their positions, 20 reducing their positions, and 15 closing their positions.
484% more call options, than puts
Call options by funds: $27.4M | Put options by funds: $4.7M
90% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 20
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
40% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 15
17% more capital invested
Capital invested by funds: $474M → $555M (+$81.3M)
6% more funds holding
Funds holding: 83 → 88 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$29.5M |
| 2 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$23.3M |
| 3 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
+$7.78M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.2M |
| 5 |
Goldman Sachs
New York
|
+$4.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$20.9M |
| 2 |
O
OrbiMed
New York
|
-$6.42M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.69M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$2.93M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.66M |
RGLS Hedge Fund Activity: Q1 2015 in Review
88 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q1 2015, worth a combined $555M — up 17% from $474M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new RGLS positions and 15 closed out — a net gain of 6 holders — while 38 added to existing stakes and 20 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $29.5M. The largest seller was RA Capital Management, cutting an estimated $20.9M.
- 88 institutional investors held Regulus Therapeutics (RGLS) as of Q1 2015, up from 83 in Q4 2014.
- Funds reported $555M of Regulus Therapeutics stock for Q1 2015, up 17% quarter-over-quarter.
- 21 funds opened new Regulus Therapeutics positions in Q1 2015 and 15 closed out, a net change of +6 holders.
- The largest Regulus Therapeutics buyer in Q1 2015 was Wellington Management Group, an estimated $29.5M added.
- The largest Regulus Therapeutics seller in Q1 2015 was RA Capital Management, an estimated $20.9M sold.
Based on aggregated 13F filings for Q1 2015.